The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix
Open accessAbstract
Programmed death-ligand 1 (PD-L1) is expressed in various immune cells and tumor cells, and is able to bind to PD-1 on T lymphocytes, thereby inhibiting their function. At present, the PD-1/PD-L1 axis is a major immunotherapeutic target for checkpoint inhibition in various cancer types, but information on the clinical significance of PD-L1 expression in cervical cancer is largely lacking. Here, we studied PD-L1 expression in paraffin-embedded samples from two cohorts of patients with cervical cancer: primary tumor samples from cohort I (squamous cell carcinoma, n=156 and adenocarcinoma, n=49) and primary and paired metastatic tumor samples from cohort II (squamous cell carcinoma, n=96 and adenocarcinoma, n=31). Squamous cell carcinomas were more frequently positive for PD-L1 and also contained more PD-L1-positive tumor-associated macrophages as compared with adenocarcinomas (both P<0.001). PD-L1-positive tumor-associated macrophages were found to express CD163 and/or CD14 by triple fluorescent immunohistochemistry, demonstrating an M2-like phenotype. Interestingly, disease-free survival (P=0.022) and disease-specific survival (P=0.046) were significantly poorer in squamous cell carcinoma patients with diffuse PD-L1 expression as compared with patients with marginal PD-L1 expression (i.e., on the interface between tumor and stroma) in primary tumors. Disease-specific survival was significantly worse in adenocarcinoma patients with PD-L1-positive tumor-associated macrophages compared with adenocarcinoma patients without PD-L1-positive tumor-associated macrophages (P=0.014). No differences in PD-L1 expression between primary tumors and paired metastatic lymph nodes were detected. However, PD-L1-positive immune cells were found in greater abundance around the metastatic tumors as compared with the paired primary tumors (P=0.001 for squamous cell carcinoma and P=0.041 for adenocarcinoma). These findings point to a key role of PD-L1 in immune escape of cervical cancer, and provide a rationale for therapeutic targeting of the PD-1/PD-L1 pathway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,293
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Powles, T., Eder, J. P., Fine, G. D., Braiteh, F. S., Loriot, Y., Cruz, C., Bellmunt, J., Burris, H. A., Petrylak, D. P., Teng, S.-L., et al. (2014) · Nature · doi:10.1038/nature13904 · Cited by 2,381
PD-L1 expression as a predictive biomarker in cancer immunotherapy
Patel, S. P., & Kurzrock, R. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0983 · Cited by 2,291
Taube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003689 · Cited by 2,157
Thompson, R. H., Kuntz, S. M., Leibovich, B. C., Dong, H., Lohse, C. M., Webster, W. S., Sengupta, S., Frank, I., Parker, A. S., Zincke, H., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4303 · Cited by 869
Waggoner, S. E. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13778-6 · Cited by 844
Lyford-Pike, S., Peng, S., Young, G. D., Taube, J. M., Westra, W. H., Akpeng, B., Bruno, T. C., Richmon, J. D., Wang, H., Bishop, J. A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2384 · Cited by 777
Programmed death ligand-1 expression in non-small cell lung cancer
Velcheti, V., Schalper, K. A., Carvajal, D. E., Anagnostou, V. K., Syrigos, K. N., Sznol, M., Herbst, R. S., Gettinger, S. N., Chen, L., & Rimm, D. L. (2014) · Laboratory Investigation · doi:10.1038/labinvest.2013.130 · Cited by 755
Smith, H. O., Tiffany, M. F., Qualls, C. R., & Key, C. R. (2000) · Gynecologic Oncology · doi:10.1006/gyno.2000.5826 · Cited by 736
Konishi, J., Yamazaki, K., Azuma, M., Kinoshita, I., Dosaka-Akita, H., & Nishimura, M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0428 · Cited by 678
Ghebeh, H., Mohammed, S., Al-Omair, A., Qattant, A., Lehe, C., Al-Qudaihi, G., Elkum, N., Alshabanah, M., Bin Amer, S., Tulbah, A., et al. (2006) · Neoplasia · doi:10.1593/neo.05733 · Cited by 612
Mu, C.-Y., Huang, J.-A., Chen, Y., Chen, C., & Zhang, X.-G. (2011) · Medical Oncology · doi:10.1007/s12032-010-9515-2 · Cited by 577
Wu, C., Zhu, Y., Jiang, J., Zhao, J., Zhang, X.-G., & Xu, N. (2006) · Acta Histochemica · doi:10.1016/j.acthis.2006.01.003 · Cited by 495
Kiyasu, J., Miyoshi, H., Hirata, A., Arakawa, F., Ichikawa, A., Niino, D., Sugita, Y., Yufu, Y., Choi, I., Abe, Y., et al. (2015) · Blood · doi:10.1182/blood-2015-02-629600 · Cited by 464
Carbognin, L., Pilotto, S., Milella, M., Vaccaro, V., Brunelli, M., Caliò, A., Cuppone, F., Sperduti, I., Giannarelli, D., Chilosi, M., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0130142 · Cited by 447
Heusinkveld, M., de Vos van Steenwijk, P. J., Goedemans, R., Ramwadhdoebe, T. H., Gorter, A., Welters, M. J. P., van Hall, T., & van der Burg, S. H. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100889 · Cited by 368
PD-L1 and Survival in Solid Tumors: A Meta-Analysis
Wu, P., Wu, D., Li, L., Chai, Y., & Huang, J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0131403 · Cited by 352
Callea, M., Albiges, L., Gupta, M., Cheng, S.-C., Genega, E. M., Fay, A. P., Song, J., Carvo, I., Bhatt, R. S., Atkins, M. B., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0043 · Cited by 347
Ritprajak, P., & Azuma, M. (2015) · Oral Oncology · doi:10.1016/j.oraloncology.2014.11.014 · Cited by 314
Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers
Mezache, L., Paniccia, B., Nyinawabera, A., & Nuovo, G. J. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.108 · Cited by 311
PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma
Cooper, W. A., Tran, T., Vilain, R. E., Madore, J., Selinger, C. I., Kohonen-Corish, M., Yip, P., Yu, B., O’Toole, S. A., McCaughan, B. C., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.05.007 · Cited by 294
Wright, A. A., Howitt, B. E., Myers, A. P., Dahlberg, S. E., Palescandolo, E., Van Hummelen, P., MacConaill, L. E., Shoni, M., Wagle, N., Jones, R. T., et al. (2013) · Cancer · doi:10.1002/cncr.28288 · Cited by 274
Karim, R., Jordanova, E. S., Piersma, S. J., Kenter, G. G., Chen, L., Boer, J. M., Melief, C. J. M., & van der Burg, S. H. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1652 · Cited by 251
Self-citationPD-L1 expression in small cell neuroendocrine carcinomas
Schultheis, A. M., Scheel, A. H., Ozretić, L., George, J., Thomas, R. K., Hagemann, T., Zander, T., Wolf, J., & Buettner, R. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2014.12.006 · Cited by 237
The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment
Pennock, G. K., & Chow, L. Q. M. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0422 · Cited by 235
Jordanova, E. S., Gorter, A., Ayachi, O., Prins, F., Durrant, L. G., Kenter, G. G., van der Burg, S. H., & Fleuren, G. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4554 · Cited by 233
Self-citationCarosella, E. D., Ploussard, G., LeMaoult, J., & Desgrandchamps, F. (2015) · European Urology · doi:10.1016/j.eururo.2015.02.032 · Cited by 227
Yang, W., Song, Y., Lu, Y., Sun, J., & Wang, H. (2013) · Immunology · doi:10.1111/imm.12101 · Cited by 205
Prognostic model for survival in patients with early stage cervical cancer
Biewenga, P., van der Velden, J., Mol, B. W. J., Stalpers, L. J. A., Schilthuis, M. S., van der Steeg, J. W., Burger, M. P. M., & Buist, M. R. (2011) · Cancer · doi:10.1002/cncr.25658 · Cited by 159
Self-citationJilaveanu, L. B., Shuch, B., Zito, C. R., Parisi, F., Barr, M., Kluger, Y., Chen, L., & Kluger, H. M. (2014) · Journal of Cancer · doi:10.7150/jca.8167 · Cited by 158
Susceptibility to cervical cancer: An overview
de Freitas, A. C., Gurgel, A. P. A. D., Chagas, B. S., Coimbra, E. C., & do Amaral, C. M. M. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.03.047 · Cited by 154
van Steenwijk, P. J. D. V., Ramwadhdoebé, T. H., Goedemans, R., Doorduijn, E. M., van Ham, J. J., Gorter, A., van Hall, T., Kuijjer, M. L., van Poelgeest, M. I. E., van der Burg, S. H., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28309 · Cited by 131
Self-citationChemoradiotherapy for cervical cancer
Rose, P. G. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00352-5 · Cited by 131
Zhang, Y., Kang, S., Shen, J., He, J., Jiang, L., Wang, W., Guo, Z., Peng, G., Chen, G., He, J., et al. (2015) · Medicine · doi:10.1097/md.0000000000000515 · Cited by 116
Heeren, A. M., Koster, B. D., Samuels, S., Ferns, D. M., Chondronasiou, D., Kenter, G. G., Jordanova, E. S., & de Gruijl, T. D. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0149 · Cited by 115
Self-citationThe prognostic significance of PD-L1 in bladder cancer
Huang, Y., Zhang, S., McCrudden, C. M., Chan, K., Lin, Y., & Kwok, H. F. (2015) · Oncology Reports · doi:10.3892/or.2015.3933 · Cited by 113
Chevolet, I., Speeckaert, R., Schreuer, M. S., Neyns, B., Krysko, O., Bachert, C., Hennart, B., Allorge, D., van Geel, N., Gele, M. V., et al. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.982382 · Cited by 113
Immune Checkpoint Modulation for Non–Small Cell Lung Cancer
Soria, J., Marabelle, A., Brahmer, J. R., & Gettinger, S. N. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2959 · Cited by 102
van de Ven, R., van den Hout, M. F. C. M., Lindenberg, J. J., Sluijter, B. J. R., van Leeuwen, P. A. M., Lougheed, S. M., Meijer, S., van den Tol, M. P., Scheper, R. J., & de Gruijl, T. D. (2011) · Blood · doi:10.1182/blood-2011-03-344838 · Cited by 100
FoxP3+ and IL-17+ cells are correlated with improved prognosis in cervical adenocarcinoma
Punt, S., van Vliet, M. E., Spaans, V. M., de Kroon, C. D., Fleuren, G. J., Gorter, A., & Jordanova, E. S. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1678-4 · Cited by 70
Self-citationSpaans, V. M., Trietsch, M. D., Peters, A. A. W., Osse, M., ter Haar, N. T., Fleuren, G. J., & Jordanova, E. S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133670 · Cited by 58
Self-citationHeeren, A. M., de Boer, E., Bleeker, M. C. G., Musters, R. J. P., Buist, M. R., Kenter, G. G., de Gruijl, T. D., & Jordanova, E. S. (2015) · Oncotarget · doi:10.18632/oncotarget.5398 · Cited by 50
Self-citationPunt, S., Houwing‐Duistermaat, J. J., Schulkens, I. A. E., Thijssen, V. L., Osse, E. M., de Kroon, C. D., Griffioen, A. W., Fleuren, G. J., Gorter, A., & Jordanova, E. S. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0350-0 · Cited by 50
Self-citationHLA-E expression in cervical adenocarcinomas: association with improved long-term survival
Spaans, V. M., Peters, A. A. W., Fleuren, G. J., & Jordanova, E. S. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-184 · Cited by 48
Self-citationvan de Ven, R., Lindenberg, J. J., Oosterhoff, D., & de Gruijl, T. D. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00403 · Cited by 42
Assays for predicting and monitoring responses to lung cancer immunotherapy.
Teixidó, C., Karachaliou, N., González‐Cao, M., Morales-Espinosa, D., & Rosell, R. (2015) · PubMed Central · doi:10.7497/j.issn.2095-3941.2015.0019 · Cited by 41
The tumor area occupied by Tbet+ cells in deeply invading cervical cancer predicts clinical outcome
Gorter, A., Prins, F. A., van Diepen, M., Punt, S., & van der Burg, S. H. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0664-0 · Cited by 21
Self-citationSamuels, S., Ferns, D. M., Meijer, D., van Straalen, J. P., Buist, M. R., Zijlmans, H. J. M. A. A., Kenter, G. G., & Jordanova, E. S. (2015) · Tissue Antigens · doi:10.1111/tan.12562 · Cited by 20
Self-citationRole of IL-12p40 in cervical carcinoma
Zijlmans, H. J. M. A. A., Punt, S., Fleuren, G. J., Trimbos, J. B., Kenter, G. G., & Gorter, A. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.488 · Cited by 18
Self-citationPrognostic value of programed death ligand 1 in patients with solid tumors: A meta-analysis
Jin, Y., Zhao, J., Shi, X., & Yu, X. (2015) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.163837 · Cited by 14
Cited by
Chung, H. C., Ros, W., Delord, J.-P., Perets, R., Italiano, A., Shapira-Frommer, R., Manzuk, L., Piha-Paul, S. A., Xu, L., Zeigenfuss, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01265 · Cited by 1,069
Frenel, J.-S., Le Tourneau, C., O’Neil, B., Ott, P. A., Piha-Paul, S. A., Gomez-Roca, C., van Brummelen, E. M. J., Rugo, H. S., Thomas, S., Saraf, S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.5471 · Cited by 531
Lo Russo, G., Moro, M., Sommariva, M., Cancila, V., Boeri, M., Centonze, G., Ferro, S., Ganzinelli, M., Gasparini, P., Huber, V., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1390 · Cited by 408
Dong, P., Xiong, Y., Yue, J., Hanley, S. J. B., & Watari, H. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00386 · Cited by 305
Lan, C., Shen, J., Wang, Y., Li, J., Liu, Z., He, M., Cao, X., Ling, J., Huang, J., Zheng, M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01920 · Cited by 210
Metadata
- Authors
- Heeren, A. M., Punt, S., Bleeker, M. C., Gaarenstroom, K. N., van der Velden, J., Kenter, G. G., de Gruijl, T. D., & Jordanova, E. S.
- Venue
- Modern Pathology
- Publisher
- Elsevier BV
- Published
- 2016-07
- Volume
- 29
- Issue
- 7
- Pages
- 753-763
- ISSN
- 0893-3952 (ISSN-L)
- OpenAlex
- W2318880831
- Cited by
- 310
- References
- 55
- FWCI
- 12.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.